Frequently Asked Questions
The market is segmented based on , By Gland (Hypothalamus, Ovaries, Pituitary Gland, Others), Hormones (Luteinizing Hormone, Kisspeptin, Others), Diseases (Polycystic Ovary Syndrome, Pituitary Tumors, Diabetes, Menopause, Cushing’s Syndrome, STDs, Polyps & Fibroids, Others), Diagnosis (Ultrasound, Blood & Urine Tests, Hysterosalpingography, Ovarian Reserve Testing, Others), Treatment (Medication, Surgery, Assisted Reproductive Technology, Others), Route of Administration (Oral, Parenteral, Implants, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029
.
The Global Hormonal Infertility Market size was valued at USD 8.32 USD Billion in 2021.
The Global Hormonal Infertility Market is projected to grow at a CAGR of 5% during the forecast period of 2022 to 2029.
The major players operating in the market include Pfizer , Merck KGaA, Sanofi, Biocare Medical LLC, Lilly, Teva Pharmaceutical Industries, Mitsubishi Chemical Group Corporation, Bristol Myers Squibb Company, GSK plc, Bayer AG, Par Pharmaceutical, TerSera Therapeutics LLC, General Electric, Koninklijke Philips N.V..
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
